tiprankstipranks
Centessa Pharmaceuticals (CNTA)
NASDAQ:CNTA

Centessa Pharmaceuticals Stock Analysis & Ratings

CNTA Stock Chart & Stats

Day’s Range$5.37 - $5.87
52-Week Range$5.37 - $26.90
Previous Close$5.54
Volume517.74K
Average Volume (3M)172.76K
Market Cap$507.72M
P/E RatioN/A
Beta1.15
Next EarningsMar 30, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score5
EPS (TTM)0.00


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

CNTA FAQ

What was Centessa Pharmaceuticals’s price range in the past 12 months?
Centessa Pharmaceuticals lowest stock price was $5.37 and its highest was $26.90 in the past 12 months.
    What is Centessa Pharmaceuticals’s market cap?
    Centessa Pharmaceuticals’s market cap is $507.72M.
      What is Centessa Pharmaceuticals’s price target?
      The average price target for Centessa Pharmaceuticals is $28.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $37.00 ,the lowest forecast is $19.00. The average price target represents 418.52% Increase from the current price of $5.4.
        What do analysts say about Centessa Pharmaceuticals?
        Centessa Pharmaceuticals’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
          When is Centessa Pharmaceuticals’s upcoming earnings report date?
          Centessa Pharmaceuticals’s upcoming earnings report date is Mar 30, 2022 which is 46 days ago.
            How were Centessa Pharmaceuticals’s earnings last quarter?
            Centessa Pharmaceuticals released its earnings results on Nov 15, 2021. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.553 by $0.103.
              Is Centessa Pharmaceuticals overvalued?
              According to Wall Street analysts Centessa Pharmaceuticals’s price is currently Undervalued.
                Does Centessa Pharmaceuticals pay dividends?
                Centessa Pharmaceuticals does not currently pay dividends.
                What is Centessa Pharmaceuticals’s EPS estimate?
                Centessa Pharmaceuticals’s EPS estimate is -$0.68.
                  How many shares outstanding does Centessa Pharmaceuticals have?
                  Centessa Pharmaceuticals has 94,020,000 shares outstanding.
                    What happened to Centessa Pharmaceuticals’s price movement after its last earnings report?
                    Centessa Pharmaceuticals reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.553. Following the earnings report the stock price went down -0.664%.
                      Which hedge fund is a major shareholder of Centessa Pharmaceuticals?
                      Among the largest hedge funds holding Centessa Pharmaceuticals’s share is RA Capital Management. It holds Centessa Pharmaceuticals’s shares valued at 40M.

                        ---

                        Centessa Pharmaceuticals Stock Analysis

                        The Centessa Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                        Learn more about TipRanks Smart Score

                        Company Description

                        Centessa Pharmaceuticals

                        Centessa Pharmaceuticals PLC is a pharmaceutical company. Its portfolio consists of preclinical to phase 3 uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. Some of its products include Vasopressin V2 Receptor Inhibitor (Lixivaptan), BMP9 Engineered Variant (MGX292), OX2R Agonist (Oral) among others.

                        ---
                        Similar Stocks
                        No data currently available

                        Popular Stocks

                        ---
                        What's Included in PREMIUM?
                        Make informed decisions based on Top Analysts' activity
                        Know what industry insiders are buying
                        Get actionable alerts from top Wall Street Analysts
                        Find out before anyone else which stock is going to shoot up
                        Get powerful stock screeners & detailed portfolio analysis